September 1, 2017 — Apixaban lowers the risk of stroke compared to warfarin in anticoagulation-naïve patients with ...
September 1, 2017 — Final results from the CASTLE-AF study show a 38 percent reduction in the composite of all-cause ...
September 1, 2017 — Biotronik recently announced data from the BIOFLOW-V randomized trial comparing Orsiro and Xience ...
Providing exceptional cardiovascular care for patients to achieve the best possible outcomes is the number one goal for ...
September 1, 2017 — Here is the list of the most popular articles and videos on the Diagnostic and Interventional ...
Cardiologists are constantly on the lookout for new methods to examine the heart using new imaging technology advances ...
Medtronic plc announced its intent to move forward with a new renal denervation pivotal trial following positive first results from a sham-controlled study in patients with high blood pressure. Investigators of the SPYRAL HTN-OFF MED Study found statistically significant and clinically important blood pressure reductions in the patients treated with renal denervation (RDN) across both office and ambulatory systolic and diastolic measurements. The data in the first 80 patients enrolled in the study at three months were presented in a late-breaking clinical trial session at the European Society of Cardiology (ESC) meeting, Aug. 26-30 in Barcelona, Spain and published simultaneously in The Lancet.
Cardiac positron emission tomography (PET) is growing in popularity among cardiologists because it provides the ability ...
August 31, 2017 — The U.S. Food and Drug Administration (FDA) has granted market clearance for SyntheticMR’s SyMRI. The ...
NaviGate Cardiac Structures Inc. (NCSI) announced that its Gate catheter-guided tricuspid atrioventricular valved stent (AVS) was implanted through the jugular vein six weeks ago into a patient’s transplanted heart that was failing due to severe tricuspid valve insufficiency. The successful implantation of the Gate AVS at the Policlinico of the University of Padua, Italy, represents the first European patient treated with the NCSI tricuspid replacement heart valve. Three hours after the intervention the patient was awake and showing improved renal function. Now, approximately two months post-procedure, the patient continues to demonstrate clinical improvement and excellent valvular function. This brings the total number of NCSI Gate tricuspid implants without 30-day mortality to three.
This video educational session, provided in partnership with the American Society of Echocardiography (ASE), is titled ...
When performing radiofrequency (RF) ablation to treat cardiac arrhythmia, medical professionals must balance the safety ...
This video educational session, provided in partnership with the American Society of Echocardiography (ASE), is titled ...
This video educational session, provided in partnership with the American Society of Echocardiography (ASE), is titled ...
This video educational session, provided in partnership with the American Society of Echocardiography (ASE), is titled ...
Change Healthcare Cardiology Hemodynamics is an integrated hemodynamic monitoring system for monitoring vital signs and ...
Vascular Dynamics Inc. announced interim results of the company’s first-in-human trial of its MobiusHD implant presented in a podium presentation at the European Society of Cardiology (ESC) in Barcelona. The data showed an average reduction of ambulatory systolic blood pressure of 20 mmHg from baseline in the first 40 patients (of an anticipated 50) to reach the six-month endpoint in studies conducted in the U.S. and E.U.
Azeem Latib, M.D., MBBCh, FCP, interventional cardiologist at Columbus Hospital in Milan, Italy, discusses the latest ...
ARTMS Products Inc. signed a strategic partnership with GE Healthcare around ARTMS’ proprietary QUANTM99 Irradiation System (QIS) for radioisotope production. The goal of the partnership is to supply equipment, technologies and research that supports the production and processing of radioisotopes on GE’s PETtrace 800 platform of medical cyclotrons. The QIS integrates on to the GE PETtrace 800 series cyclotron to enable an alternative, non-reactor supply of valuable medical isotopes including technetium-99m, copper-64, gallium-68 and zirconium-89.